-

Cencora Announces Common Share Repurchase From Walgreens Boots Alliance

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of approximately $50 million in concurrence with Walgreens Boots Alliance’s sale of Cencora shares pursuant to Rule 144 under the Securities Act of 1933, as amended.

Cencora intends to repurchase shares from Walgreens Boots Alliance at the price per share equal to the price in the Rule 144 sale. The concurrent share repurchase will be made under Cencora’s share repurchase program and the repurchased shares will be held in treasury.

About Cencora

Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. Our 46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our responsibility to create healthier futures. Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more than $250 billion in annual revenue. Learn more at investor.cencora.com

Contacts

Bennett S. Murphy
Senior Vice President, Head of Investor Relations & Treasury
610-727-3693
Bennett.Murphy@cencora.com

Industry:

Cencora

NYSE:COR
Release Versions
English

Contacts

Bennett S. Murphy
Senior Vice President, Head of Investor Relations & Treasury
610-727-3693
Bennett.Murphy@cencora.com

More News From Cencora

Cencora Reports Fiscal 2026 Second Quarter Results

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2026 second quarter ended March 31, 2026, revenue increased 3.8 percent year-over-year to $78.4 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $8.40 for the second quarter of fiscal 2026 compared to $3.68 in the prior year second quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below,...

Cencora Announces Date and Time for Second Quarter Fiscal 2026 Earnings Release

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2026 on Wednesday, May 6, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on May 6, 2026. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Fin...

Cencora to Expand Retina Consultants of America Through Acquisition of EyeSouth Partners’ Retina Business

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced the signing of a definitive agreement to acquire EyeSouth Partners’ retina business for $1.1 billion. Upon completion of the transaction, the affiliated retina physicians of EyeSouth Partners will join Cencora’s Retina Consultants of America (“RCA”), a leading management services organization (MSO). “Driven by a commitment to empower ophthalmologists, EyeSouth Partners has built a strong regional network of physicians...
Back to Newsroom